Martin Haluzík: Metabolic Risk Factors and Therapeutic Opportunities in Cardiovascular Disease
Martin Haluzík, Professor of Medicine at Institute for Clinical and Experimental Medicine, shared a post on LinkedIn about a recent article by Paul C Evans et al, published in European Heart Journal:
“A novel scientific statement of the Esc: Novel caridovascular metabolic risk factor mechanisms and therapeutic opportunities.
Very intersting paper just published in European Heart Journal by Paul C Evans and colleagues.
Metabolic disorders such as obesity, type 2 diabetes, and dyslipidaemia are major drivers of cardiovascular risk and have reached epidemic levels in Western populations.
Recent advances in clinical research have uncovered unexpected and often beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes, revealing complex interactions between metabolism and cardiac pathology.
Despite their clinical efficacy, the molecular and cellular mechanisms through which many of these agents act remain only partially understood.
This gap in knowledge underscores the urgent need for fundamental research that not only dissects the biology of metabolic disorders and cardiovascular disease but also reveals the mechanistic basis of existing and emerging therapies, thereby enabling rational therapeutic development.
This scientific statement, developed by researchers from the European Society of Cardiology (ESC) Council on Basic Cardiovascular Science and several ESC Working Groups, provides a state-of-the-art overview of the emerging molecular and cellular pathways linking metabolic abnormalities with vascular and cardiac disease.
By illuminating these critical connections and unresolved questions, this article aims to catalyse innovation in the prevention and management of cardiovascular disease in the context of metabolic dysfunction and to suggest new directions for future research.
- Excellent summary of current knowledge on interconnection between metabolic risk factor mechanisms and therapeutic opportunities of cardiovascular diseases
- Cardiac metabolic flexibility in health and disease
- Perfect summary of gaps in knowledge and future directions of research and much more.”
Title: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities: A scientific statement of the ESC Council on Basic Cardiovascular Science, the ESC Working Group on Atherosclerosis and Vascular Biology, the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Myocardial Function, and the ESC Working Group on Cardiac Cellular Electrophysiology
Authors: Paul C Evans, Gemma Vilahur, Petra Kleinbongard, Elena Osto, Carol Ann Remme, Rosalinda Madonna, Dunja Aksentijevic, Harald Sourij, Sean M Davidson, Donato Santovito, Jürgen Gindlhuber, Christian Weber, Wolfgang A Linke, Esther Lutgens, Luc Bertrand, Dana Dawson, Magnus Bäck, G Danilo Norata, Johann Wojta, Cinzia Perrino
Read the Full Article on European Heart Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 14, 2026, 16:10Raffaella Colombatti: Proud to Have Authored the New Lancet Seminar on Sickle Cell Disease
-
Mar 14, 2026, 16:05Simon Senanu: D-Dimer – A Small Fragment with Big Clinical Significance
-
Mar 14, 2026, 15:53Ney Carter: Key Advances in the 2026 ACC/AHA Guideline on the Management of Dyslipidemia
-
Mar 14, 2026, 15:45Nicole Odofin: The First Blood Drive Event at Channel 4
-
Mar 14, 2026, 15:41Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
-
Mar 14, 2026, 15:40Jecko Thachil: Anticoagulation in Patients With Metabolic-Associated Fatty Liver Disease
-
Mar 14, 2026, 15:37Lorenz Räber: New Insights Into Silent Plaque Ruptures in AMI Patients
-
Mar 14, 2026, 15:11Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE
-
Mar 14, 2026, 15:09Cedric Hermans: New Viewpoint on the Challenges of Coagulation Rebalancing in Hemophilia